December 2003 Cover
|
 |
A recent study suggests that six months after beginning HAART may be the optimum time for determining a patient's prognosis, rather than before the start of treatment.
Scientists found that patients with high CD4 cell counts and lower viral load at HAART initiation ran lower risks of AIDS or death six months after beginning therapy. However, measurements of CD4 cells and viral load at the time of starting HAART were not indicative of prognosis once the six-month assessment had been
taken into account. "At six months after starting HAART," one researcher said, "the current CD4 cell count and viral load, but not the values before the start of therapy, are strongly associated with subsequent disease progression. Our findings should inform guidelines on when to modify HAART in this group of patients who had not
previously received antiretroviral therapy."
Editor's Note: from AIDS Weekly
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
